Free Trial
NASDAQ:GPCR

Structure Therapeutics Q2 2025 Earnings Report

Structure Therapeutics logo
$18.53 -0.63 (-3.29%)
Closing price 04:00 PM Eastern
Extended Trading
$18.93 +0.40 (+2.16%)
As of 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Structure Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.28
Beat/Miss
N/A
One Year Ago EPS
N/A

Structure Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Structure Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Structure Therapeutics Earnings Headlines

He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.
Equities Analysts Set Expectations for GPCR FY2025 Earnings
GPCR FY2025 EPS Estimate Cut by Cantor Fitzgerald
Leerink Partnrs Has Negative Estimate for GPCR Q3 Earnings
See More Structure Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Structure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Structure Therapeutics and other key companies, straight to your email.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

View Structure Therapeutics Profile

More Earnings Resources from MarketBeat